Regal Assets Analytics

SanaCurrents capturing gain after Spectrum’s (SPPI) PDUFA catalyst up 92%; closing out BioXcel (BTAI)

By |2022-04-26T08:59:56-04:00April 5th, 2022|Tags: , |

Since SanaCurrents issued a report on Spectrum Pharmaceuticals’ (SPPI) cancer drug poziotinib on February 25, the company’s stock price has climbed 92%, closing [...]

Immunocore (IMCR) Gains FDA Approval For Tebentafusp In Uveal Melanoma; SanaCurrents Closing Coverage

By |2022-02-07T08:27:36-05:00January 26th, 2022|Tags: |

UK-based Immunocore Holdings plc (NASDAQ:IMCR) said on January 26 before the markets opened the FDA had approved the company’s biologic [...]

SanaCurrents Closed Coverage of Annexon (ANNX) on Conflicting Phase II Interim Data in Huntington’s Disease

By |2022-01-08T13:02:51-05:00January 7th, 2022|Tags: |

When SanaCurrents issued its report on October 30, 2020, Annexon’s stock closed at $20.81 per share. The stock reached a high of $33.89 per share in March 2021 before leveling to a $20 to $22 per share range between May and mid-October. Annexon began to feel the biotech pull back in the latter months of last year, dropping to slightly more than $10 per share.

Portfolio Update: Closing out ARCT, BTCY, MRNS, KRON, AFIB; new approach to PDUFA catalysts

By |2022-01-08T10:12:03-05:00December 29th, 2021|Tags: , , , , |

As noted in November 2021, Arcturus Therapeutics (NASDAQ:ARCT) was at the forefront of the Covid19 pandemic, teaming up in January [...]

Calliditas’ (CALT) IgAN drug gains FDA approval; SanaCurrents closing out coverage

By |2021-12-20T08:47:54-05:00December 16th, 2021|Tags: |

After the markets closed on December 15, Calliditas Therapeutics said the FDA granted accelerated approval to TARPEYO (budesonide), formerly named [...]

Codiak (CDAK) to report early exoSTING data; SanaCurrents closing coverage

By |2021-11-09T10:11:51-05:00November 8th, 2021|Tags: |

When SanaCurrents issued a March 19 report forecasting a positive outcome for Codiak Biosciences’ (NASDAQ:CDAK) phase I/II exoSTING trial, the favorable outlook was based [...]

Go to Top